Genital Diseases, Male  >>  Provenge (sipuleucel-T)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Provenge (sipuleucel-T) / Bausch Health
NCT01133704: Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

Completed
3
98
US
sipuleucel-T, APC-Placebo
Dendreon
Hormone-Refractory Prostate Cancer
03/03
05/05
NCT00005947: Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Completed
3
127
US
sipuleucel-T, APC8015, Provenge, Placebo
Dendreon
Prostate Cancer
09/04
09/04
PROTECT, NCT00779402: PROvenge Treatment and Early Cancer Treatment

Completed
3
176
US
Control, Sipuleucel-T, Provenge®, APC8015
Dendreon
Prostate Cancer
08/06
05/15
NCT00065442: Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Completed
3
512
US, Canada
Sipuleucel-T, APC-Placebo
Dendreon
Prostate Cancer
01/09
01/09

Download Options